Comparative evaluation of the effectiveness and side effects of different ways of misoprostol Prescribed in the termination of the second trimester of pregnancy

Comparison of the effectiveness and side effects of different ways of misoprostol Prescribed in the termination of the second trimester of pregnancy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015123014333N47

Enrollment

180

Registered

2016-01-17

Start date

2016-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medical abortion. Medical abortion

Interventions

Intervention 1: In the first group misoprostol 400 mcg is selected that in every 4 hours up to 5 doses will be Prescribed in the form of vaginally.Vital signs and adverse effects in beginning of each

Treatment - Drugs

In the first group misoprostol 400 mcg is selected that in every 4 hours up to 5 doses will be Prescribed in the form of vaginally.Vital signs and adverse effects in beginning of each dose (hour 1) an

In the second group misoprostol 400 mcg is selected that in every 4 hours up to 5 doses in the form of orally will be Prescribed. Vital signs and adverse effects in beginning of each dose (hour 1) and

In the thired group misoprostol 400 mcg is selected that in every 4 hours up to 5 doses will be Prescribed sublingual. Vital signs and adverse effects in beginning of each dose (hour 1) and 4 hours af

Eligibility

Sex/Gender

Female

Age

3 Months to 6 Months

Inclusion criteria

Inclusion criteria: Inclusion criteria: singleton pregnancy;gestational age 13 to 22 with an indication for termination of pregnancy in medical procedures; Chorioamnionitis. Exclusion criteria: patients with a history of caesarean section; mother serious systemic and chronic disease , cardiovascular, renal diseases ; known sensitivity to prostaglandins and coagulopathy; uncontrolled seizure disorders; hemolytic disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ague. Timepoint: Baseline and 4 hours after drug administration. Method of measurement: By asking of patient.;Abdominal pain. Timepoint: Baseline and 4 hours after drug administration. Method of measurement: By asking of patient.;Nausea. Timepoint: Baseline and 4 hours after drug administration. Method of measurement: By asking of patient.;Vaginal bleeding. Timepoint: Baseline and 4 hours after drug administration. Method of measurement: By asking of patient and doctor observation.;Vomiting. Timepoint: Baseline and 4 hours after drug administration. Method of measurement: By asking of patient.;During the induction of abortion. Timepoint: From the intervention to discharge pregnancy products. Method of measurement: Based on clinical signs and doctor observation.	—

Measure

Time frame

Ague. Timepoint: Baseline and 4 hours after drug administration. Method of measurement: By asking of patient.;Abdominal pain. Timepoint: Baseline and 4 hours after drug administration. Method of measurement: By asking of patient.;Nausea. Timepoint: Baseline and 4 hours after drug administration. Method of measurement: By asking of patient.;Vaginal bleeding. Timepoint: Baseline and 4 hours after drug administration. Method of measurement: By asking of patient and doctor observation.;Vomiting. Timepoint: Baseline and 4 hours after drug administration. Method of measurement: By asking of patient.;During the induction of abortion. Timepoint: From the intervention to discharge pregnancy products. Method of measurement: Based on clinical signs and doctor observation.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026